Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine Infusions in Treatment-Resistant Depression
NCT03742557Phase 3Unknown
- Start
- Oct 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in treatment-resistant depression (TRD) comparing Ketamine First with Placebo First (2 arms). Primary endpoints: Hamilton Depression Rating Scale, Glutamate levels in pgACC and 2 more. Status: unknown.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT03742557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03742557.